United Asset Strategies Inc. Acquires 4,885 Shares of Gilead Sciences, Inc. (GILD)
United Asset Strategies Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 70,826 shares of the biopharmaceutical company’s stock after buying an additional 4,885 shares during the period. Gilead Sciences accounts for approximately 3.3% of United Asset Strategies Inc.’s holdings, making the stock its 4th largest holding. United Asset Strategies Inc.’s holdings in Gilead Sciences were worth $5,738,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the business. Hanson & Doremus Investment Management increased its holdings in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $147,000. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares during the last quarter. Rowland & Co. Investment Counsel ADV purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $153,000. Finally, Capstone Investment Advisors Netherlands B.V. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $172,000. 76.11% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have issued reports on GILD shares. Jefferies Group restated a “hold” rating and set a $93.00 price objective on shares of Gilead Sciences in a report on Wednesday, October 4th. Bank of America decreased their target price on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research report on Wednesday, October 4th. Oppenheimer began coverage on Gilead Sciences in a research report on Thursday, October 5th. They issued a “market perform” rating for the company. CIBC began coverage on Gilead Sciences in a research report on Thursday, October 5th. They issued a “market perform” rating for the company. Finally, Leerink Swann lifted their target price on Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research report on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and seventeen have assigned a buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $85.58.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the previous year, the business earned $2.75 EPS. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. research analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
In other news, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP James R. Meyers sold 100,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the sale, the executive vice president now directly owns 102,715 shares in the company, valued at $8,241,851.60. The disclosure for this sale can be found here. Insiders sold a total of 591,666 shares of company stock worth $44,466,567 in the last three months. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.